DiMarchi, Richard D.

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 1,868

Anti-obesity drug discovery: advances and challenges

Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 1,021

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 696

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 645

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 641

The New Biology and Pharmacology of Glucagon

Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 419

The metabolic actions of glucagon revisited

Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 406

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 322

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 321

Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism

Andrews, Z. B., Erion, D., Beiler, R., Liu, Z.-W., Abizaid, A., Zigman, J., Elsworth, J. D., Savitt, J. M., DiMarchi, R., Tschöp, M., et al. (2009) · The Journal of Neuroscience

Parkinson's Disease Mechanisms and TreatmentsRegulation of Appetite and Obesity

Cited by 289

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes

Fibroblast Growth Factor ResearchPancreatic function and diabetes

Cited by 245

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 229

Anti-obesity therapy: from rainbow pills to polyagonists

Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 199

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell

Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic Diseases

Cited by 191

Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity

Nogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., López, M., et al. (2009) · The Journal of Neuroscience

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 182

Reappraisal of GIP Pharmacology for Metabolic Diseases

Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 180

GLP-1/glucagon receptor co-agonism for treatment of obesity

Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 175

Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21

Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 156

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 153

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 152

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 149

Targeted pharmacological therapy restores β-cell function for diabetes remission

Sachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Böttcher, A., Sánchez-Garrido, M. A., Tarquis-Medina, M., Kleinert, M., Fischer, K., Jall, S., et al. (2020) · Nature Metabolism

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 147

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 146

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 133